Gilead's HCV treatment available for access by spring

Amy Schofield 22 February 2018

NICE has issued a technology appraisal guidance for Gilead Science’s Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg, 'SOF/VEL/VOX'), a 12-week treatment regimen for patients with any genotype of chronic HCV infection, without cirrhosis or with compensated cirrhosis, who have previously failed therapy with a direct-acting antiviral (DAA) - containing regimen.
SOF/VEL/VOX, a 12-week treatment regimen, fulfils an unmet need for people who have had unsuccessful treatment with DAA. Treatment with SOF/VEL/VOX represents the best hope of cure for this population of people with HCV.

On 28 January, NHS England announced its commitment to being the first country in the world to eliminate hepatitis C by 2025. The availability of SOF/VEL/VOX is a critical step towards this goal, as treatments for all people infected with HCV are now available, regardless of genotype, disease state or treatment status.

Vosevi is Gilead’s fourth sofosbuvir-based treatment to be recommended for the treatment of chronic HCV infection, and complements the existing portfolio in demonstrating high cure rates across a range of DAA experienced and naïve patients.

Sofosbuvir-based regimens are recommended by global guidelines across HCV genotypes and disease severities, and have been used to treat more than 1.5 million people worldwide.


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.